WO2007126788A3 - Methods and compositions for the treatment and prevention of viral infection - Google Patents

Methods and compositions for the treatment and prevention of viral infection Download PDF

Info

Publication number
WO2007126788A3
WO2007126788A3 PCT/US2007/007529 US2007007529W WO2007126788A3 WO 2007126788 A3 WO2007126788 A3 WO 2007126788A3 US 2007007529 W US2007007529 W US 2007007529W WO 2007126788 A3 WO2007126788 A3 WO 2007126788A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
compositions
viral infection
prevention
Prior art date
Application number
PCT/US2007/007529
Other languages
French (fr)
Other versions
WO2007126788A2 (en
Inventor
Zhiping Ye
Hang Xie
Teresa M Liu
Hong Chen
Original Assignee
Us Gov Health & Human Serv
Zhiping Ye
Hang Xie
Teresa M Liu
Hong Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Zhiping Ye, Hang Xie, Teresa M Liu, Hong Chen filed Critical Us Gov Health & Human Serv
Publication of WO2007126788A2 publication Critical patent/WO2007126788A2/en
Publication of WO2007126788A3 publication Critical patent/WO2007126788A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The instant invention provides nucleic acid molecules comprising a nucleic acid segment encoding a viral surface protein and a nucleic acid segment encoding a viral matrix protein for the immunization of treatment of viral infections. The invention also provides compositions and methods for treating or immunizing subjects having or at risk of having a viral infection.
PCT/US2007/007529 2006-03-27 2007-03-27 Methods and compositions for the treatment and prevention of viral infection WO2007126788A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78674706P 2006-03-27 2006-03-27
US60/786,747 2006-03-27

Publications (2)

Publication Number Publication Date
WO2007126788A2 WO2007126788A2 (en) 2007-11-08
WO2007126788A3 true WO2007126788A3 (en) 2008-02-28

Family

ID=38529381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007529 WO2007126788A2 (en) 2006-03-27 2007-03-27 Methods and compositions for the treatment and prevention of viral infection

Country Status (1)

Country Link
WO (1) WO2007126788A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107002119A (en) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 Treatment of cancer and the former and associating that HGF is expressed using C MET antagonists
CN107326103B (en) * 2017-08-28 2021-06-15 聊城大学 Triple RT-PCR specific amplification primer group and triple-identification RT-PCR detection method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000885A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
WO2005020889A2 (en) * 2003-07-11 2005-03-10 Novavax, Inc. Functional influenza virus-like particles (vlps)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
WO2002000885A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
WO2005020889A2 (en) * 2003-07-11 2005-03-10 Novavax, Inc. Functional influenza virus-like particles (vlps)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALI A ET AL: "Influenza virus assembly: Effect of influenza virus glycoproteins on the membrane association of M1 protein", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 18, September 2000 (2000-09-01), pages 8709 - 8719, XP002982630, ISSN: 0022-538X *
CHERBONNEL M ET AL: "Strategies to improve protection against low-pathogenicity H7 avian influenza virus infection using DNA vaccines", AVIAN DISEASES, AMERICAN ASSOCIATION OF AVIAN PATHOLOGISTS, KENNET SQ., PA, US, vol. 47, no. special issue, 2003, pages 1181 - 1186, XP009090341, ISSN: 0005-2086 *
FORDE GARETH M: "Rapid-response vaccines--does DNA offer a solution?", NATURE BIOTECHNOLOGY SEP 2005, vol. 23, no. 9, September 2005 (2005-09-01), pages 1059 - 1062, XP002454456, ISSN: 1087-0156 *
LATHAM T ET AL: "Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 13, July 2001 (2001-07-01), pages 6154 - 6165, XP002323947, ISSN: 0022-538X *
PUSHKO ET AL: "Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 50, 30 December 2005 (2005-12-30), pages 5751 - 5759, XP005180698, ISSN: 0264-410X *
RAVIPRAKASH K ET AL: "Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 22, May 2000 (2000-05-01), pages 2426 - 2434, XP004192987, ISSN: 0264-410X *

Also Published As

Publication number Publication date
WO2007126788A2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
WO2008028946A3 (en) Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2007056457A3 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007030810A3 (en) Multiparameter whole blood monitor and method
WO2008079372A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
EP4219566A3 (en) Recombinant rsv antigens
WO2008115281A3 (en) Compounds for treating viral infections
WO2009152147A3 (en) Compositions and methods for dengue virus (dv) treatment and vaccination
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
EP2192901A4 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
WO2008089144A3 (en) Improved dna vaccination protocols
WO2008088524A3 (en) Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
HK1124084A1 (en) Nucleic acid for treatment or prevention of immunodeficiency virus infection
WO2008053478A3 (en) Compositions and methods for inhibiting hiv-1 replication and integrase activity
WO2008057158A3 (en) Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications
WO2007110709A3 (en) Formulations of tipifarnib for intravenous administration
WO2006085979A3 (en) Soluble forms of hendra and nipah virus g glycoprotein
WO2009033183A3 (en) Compounds and methods for treatment of hcv and conditions associated with cd81 binding

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754100

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07754100

Country of ref document: EP

Kind code of ref document: A2